Kerri Pillar
Primary Care · Victoria, TXNPI 1619406592
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $738 and has fallen 56.4% since, to $322 in 2025.
Across 157 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$338
- Novo Nordisk$305
- Amgen$262
- Astellas Pharma US Inc$245
- AbbVie$220
- GSK$197
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,74496%
- Education$1144%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 25 | $338 |
| Novo Nordisk | 18 | $305 |
| Amgen(2 entities) | 18 | $262 |
| Astellas Pharma US Inc | 11 | $245 |
| AbbVie | 13 | $220 |
| GSK | 8 | $197 |
| AstraZeneca | 10 | $179 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $175 |
| Pfizer | 7 | $137 |
| Boehringer Ingelheim | 3 | $118 |
| Bayer | 5 | $88 |
| Idorsia Pharmaceuticals US Inc | 5 | $80 |
| Exact Sciences | 4 | $67 |
| Radius Health, Inc. | 3 | $66 |
| Merck | 3 | $48 |
| Supernus Pharmaceuticals, Inc. | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Corcept Therapeutics | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Genentech USA, Inc. | 3 | $26 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Corium, LLC | 1 | $17 |
| Vivus LLC | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$107
How this compares
$2,857 in reported general payments places this provider in the 85th percentile of 563 primary care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 180 | $194,305 |
| OzempicSemaglutide | 58 | $66,577 |
| TrulicityDulaglutide | 39 | $38,358 |
| EliquisApixaban | 39 | $38,174 |
| JanuviaSitagliptin Phosphate | 17 | $27,431 |
| VascepaIcosapent Ethyl | 24 | $23,846 |
| KerendiaFinerenone | 20 | $20,895 |
| FarxigaDapagliflozin Propanediol | 20 | $16,059 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $11,940 |
| Repatha SureclickEvolocumab | 15 | $8,482 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,468 |
| Icosapent Ethyl | 22 | $5,738 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,595 |
| HumalogInsulin Lispro | 12 | $3,462 |
| Levothyroxine Sodium | 244 | $2,430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $338 | $236,125231 claims |
| Novo NordiskOzempic | $305 | $66,57758 claims |
| PfizerEliquis | $137 | $38,17439 claims |
| MerckJanuvia | $48 | $27,43117 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $179 | $22,52831 claims |
| BayerKerendia | $88 | $20,89520 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $197 | $16,53523 claims |
| AbbVieArmour Thyroid, Synthroid | $220 | $2,46143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 563 primary care providers in Texas.
Other primary care in Victoria
- Mary GibbensHouston$42K
- Phillip GulleySan Antonio$23K
- Herbert BautistaDallas$14K
- Brandi JoynerLongview$12K
- Steven ParisAustin$10K
- Hope OdomCollege Station$10K
- Arlena GraysTomball$9K
- Charlotte BallardSan Antonio$9K
- Hannah LancasterMcKinney$9K
- Jacqueline MilesGrand Prairie$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.